CL2017003152A1 - Composiciones de hidroxipropil beta-ciclodextrina y métodos - Google Patents
Composiciones de hidroxipropil beta-ciclodextrina y métodosInfo
- Publication number
- CL2017003152A1 CL2017003152A1 CL2017003152A CL2017003152A CL2017003152A1 CL 2017003152 A1 CL2017003152 A1 CL 2017003152A1 CL 2017003152 A CL2017003152 A CL 2017003152A CL 2017003152 A CL2017003152 A CL 2017003152A CL 2017003152 A1 CL2017003152 A1 CL 2017003152A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- mixtures
- hydroxypropyl beta
- cyclodextrin compositions
- intratecal
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 4
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 238000000185 intracerebroventricular administration Methods 0.000 abstract 2
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- 239000001116 FEMA 4028 Substances 0.000 abstract 1
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 abstract 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 abstract 1
- 229960004853 betadex Drugs 0.000 abstract 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical group [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 abstract 1
- 238000012797 qualification Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
<p>LA PRESENTE INVENCIÓN PROPORCIONA MEZCLAS DE MOLÉCULAS DE BETA–CICLODEXTRINAS SUSTITUIDAS EN UNA O MÁS POSICIONES HIDROXILO CON GRUPOS HIDROXIPROPILO, DONDE LA MEZCLA, EN FORMA OPCIONAL, INCLUYE MOLÉCULAS DE BETA–CICLODEXTRINAS NO SUSTITUIDAS, PARA EL USO COMO UN INGREDIENTE FARMACÉUTICAMENTE ACTIVO; MÉTODOS DE ELABORACIÓN DE DICHAS MEZCLAS; MÉTODOS DE CALIFICACIÓN DE DICHAS MEZCLAS PARA EL USO EN UNA COMPOSICIÓN FARMACÉUTICA ADECUADA PARA LA ADMINISTRACIÓN INTRATECAL O INTRACEREBROVENTRICULAR; COMPOSICIONES FARMACÉUTICAS ADECUADAS PARA LA ADMINISTRACIÓN INTRATECAL O INTRACEREBROVENTRICULAR QUE COMPRENDEN DICHAS MEZCLAS; Y MÉTODOS DE USO DE LAS COMPOSICIONES FARMACÉUTICAS PARA EL TRATAMIENTO DE LA ENFERMEDAD DE NIEMANN–PICK TIPO C.</p>
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562173889P | 2015-06-10 | 2015-06-10 | |
| US201562175075P | 2015-06-12 | 2015-06-12 | |
| US201562189114P | 2015-07-06 | 2015-07-06 | |
| US201562245974P | 2015-10-23 | 2015-10-23 | |
| US201562249876P | 2015-11-02 | 2015-11-02 | |
| US201562263599P | 2015-12-04 | 2015-12-04 | |
| US201662276728P | 2016-01-08 | 2016-01-08 | |
| US201662308736P | 2016-03-15 | 2016-03-15 | |
| US201662314765P | 2016-03-29 | 2016-03-29 | |
| US201662331385P | 2016-05-03 | 2016-05-03 | |
| US201662345721P | 2016-06-03 | 2016-06-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017003152A1 true CL2017003152A1 (es) | 2018-04-27 |
Family
ID=57504353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017003152A CL2017003152A1 (es) | 2015-06-10 | 2017-12-07 | Composiciones de hidroxipropil beta-ciclodextrina y métodos |
Country Status (16)
| Country | Link |
|---|---|
| US (48) | US20160361345A1 (es) |
| EP (1) | EP3307278A4 (es) |
| JP (1) | JP2018517046A (es) |
| KR (1) | KR20180035787A (es) |
| CN (1) | CN107847517A (es) |
| AU (1) | AU2016276774A1 (es) |
| BR (1) | BR112017026287A2 (es) |
| CA (1) | CA2988529A1 (es) |
| CL (1) | CL2017003152A1 (es) |
| EA (1) | EA033892B1 (es) |
| HK (1) | HK1247856A1 (es) |
| IL (1) | IL255991A (es) |
| MX (1) | MX2017015879A (es) |
| TW (1) | TW201716070A (es) |
| WO (1) | WO2016201137A1 (es) |
| ZA (1) | ZA201708414B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016276774A1 (en) | 2015-06-10 | 2018-01-18 | Vtesse, Inc. | Hydroxypropyl beta-cyclodextrin compositions and methods |
| KR101906578B1 (ko) * | 2017-07-28 | 2018-10-10 | 경북대학교 산학협력단 | 사이클로덱스트린 및 vegf 과발현 줄기세포를 유효성분으로 포함하는 퇴행성 신경질환의 예방 또는 치료용 약학적 조성물 |
| LU100797B1 (en) | 2018-05-15 | 2019-11-15 | Univ Luxembourg | 2-hydroxypropyl-beta-cyclodextrin for use in a method of treatment of a parkinsonian condition |
| US12522670B2 (en) | 2018-06-29 | 2026-01-13 | Roquette Freres | Hydroxypropyl-beta-cyclodextrin and process for the production thereof |
| FR3083234B1 (fr) | 2018-06-29 | 2020-11-27 | Roquette Freres | Nouvelles hydroxypropyl-beta-cyclodextrines et leurs procedes de preparation |
| EP3873604B1 (en) * | 2018-10-29 | 2024-08-21 | Cyclo Therapeutics, Inc. | Methods for treating alzheimer's disease with hp-[beta]-cyclodextrin |
| AU2020204925B2 (en) | 2019-01-03 | 2025-11-20 | Cyclarity Therapeutics, Inc. | Cyclodextrin dimers, compositions thereof, and uses thereof |
| US20220211813A1 (en) * | 2019-04-12 | 2022-07-07 | Loma Linda University | Methods for treatment of niemann-pick disease type c |
| US11446325B2 (en) | 2020-09-30 | 2022-09-20 | Cyclolab Cyclodextrin Research And Development Laboratory Ltd. | Cyclodextrin derivatives in the treatment or prevention of lysosomal neurodegenerative diseases |
| CN113457468B (zh) * | 2021-06-24 | 2022-10-28 | 北京工业大学 | 一种单宁酸-羟丙基β环糊精复合纳滤膜及其制备方法 |
| JP2025506676A (ja) | 2022-02-18 | 2025-03-13 | ベレン セラピューティクス ピー．ビー．シー． | ヒドロキシプロピル－ベータ－シクロデキストリンの組成物及びその精製方法 |
| KR20250024808A (ko) * | 2022-06-13 | 2025-02-19 | 베렌 테라퓨틱스 피.비.씨. | 하이드록시프로필-베타-사이클로덱스트린 제조를 위한 시스템 및 방법 |
| JP7899984B2 (ja) * | 2022-10-28 | 2026-08-04 | 国立大学法人 熊本大学 | 細胞内コレステロール輸送障害に起因する疾患又は障害の治療、予防又は改善用組成物 |
| WO2026022777A1 (en) | 2024-07-26 | 2026-01-29 | Beren Therapeutics P.B.C. | 2-hydroxypropyl beta-cyclodextrins for use in a method of treating niemann-pick disease type c in subjects with infantile onset |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US6407079B1 (en) | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
| US4877778A (en) | 1987-07-01 | 1989-10-31 | The Children's Medical Center Corporation | Method of enhancing lipophile transport using cyclodextrin derivatives |
| WO1990012035A1 (en) | 1989-04-03 | 1990-10-18 | Janssen Pharmaceutica N.V. | Regioselective substitutions in cyclodextrins |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US5262404A (en) | 1990-02-15 | 1993-11-16 | The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation | Cyclodextrin polymers and cyclodextrins immobilized on a solid surface |
| WO1993007904A1 (en) | 1991-10-16 | 1993-04-29 | Schering Corporation | Lipophilic oligosaccharide antibiotic salt compositions |
| EP0803243B1 (en) * | 1996-04-24 | 2003-03-19 | Pfizer Inc. | Cyclodextrins and phenolic compounds in dental products |
| FR2767834B1 (fr) | 1997-08-29 | 1999-12-03 | Inst Francais Du Petrole | Mono et di-derives de cyclodextrines, leurs synthese et purification et leur utilisation en support |
| AU2001259725A1 (en) * | 2000-05-15 | 2001-11-26 | The Procter And Gamble Company | Compositions comprising cyclodextrin derivatives |
| US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| WO2005112637A1 (en) | 2004-05-14 | 2005-12-01 | Decode Chemistry, Inc. | Formulations for non-parenteral use including hydrophobic cyclodextrins |
| EP1655034A1 (en) * | 2004-10-10 | 2006-05-10 | Université de Liège | Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases. |
| EP1747785A1 (en) | 2005-07-28 | 2007-01-31 | Istituto Clinico Humanitas | Cyclodextrins for blood detoxification |
| US20090258001A1 (en) | 2006-06-06 | 2009-10-15 | Paul Ponath | Administration of anti-CD3 antibodies in the treatment of autoimmune diseases |
| US20120077774A1 (en) | 2009-05-28 | 2012-03-29 | Cornell University | Compositions and their use for removing cholesterol |
| US9044451B2 (en) | 2010-07-19 | 2015-06-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of delta tocopherol for the treatment of lysosomal storage disorders |
| CN102040675B (zh) | 2010-12-22 | 2012-10-03 | 石药集团中诺药业（石家庄）有限公司 | 一种羟丙基-β-环糊精的制备方法 |
| WO2013155485A2 (en) | 2012-04-13 | 2013-10-17 | Alessia Fornoni | Method of using cyclodextrin |
| CA2880880C (en) | 2012-08-03 | 2021-01-26 | John Mckew | Cyclodextrin for the treatment of lysosomal storage diseases |
| JP6367211B2 (ja) | 2012-11-16 | 2018-08-01 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | リソソーム蓄積症の改善物質としてのトコフェロール誘導体およびトコフェリルキノン誘導体 |
| FR3014694B1 (fr) * | 2013-12-13 | 2016-11-11 | Roquette Freres | Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl |
| AU2016276774A1 (en) | 2015-06-10 | 2018-01-18 | Vtesse, Inc. | Hydroxypropyl beta-cyclodextrin compositions and methods |
| US12522670B2 (en) | 2018-06-29 | 2026-01-13 | Roquette Freres | Hydroxypropyl-beta-cyclodextrin and process for the production thereof |
| EP3873604B1 (en) | 2018-10-29 | 2024-08-21 | Cyclo Therapeutics, Inc. | Methods for treating alzheimer's disease with hp-[beta]-cyclodextrin |
| CN109675054A (zh) | 2018-12-28 | 2019-04-26 | 云南民族大学 | 一种高丽槐素-羟丙基-β-环糊精包合物及其制备方法 |
| EP4028038A4 (en) | 2019-09-13 | 2024-01-17 | Board of Regents, The University of Texas System | PEPTIDE COMPOSITIONS AND METHODS OF TREATING ALZHEIMER'S DISEASE |
| US20230330133A1 (en) | 2020-08-27 | 2023-10-19 | Beren Therapeutics P.B.C. | Methods for the treatment of cholesterol crystal embolization with cyclodextrins |
| JP2025506676A (ja) | 2022-02-18 | 2025-03-13 | ベレン セラピューティクス ピー．ビー．シー． | ヒドロキシプロピル－ベータ－シクロデキストリンの組成物及びその精製方法 |
-
2016
- 2016-06-09 AU AU2016276774A patent/AU2016276774A1/en not_active Abandoned
- 2016-06-09 KR KR1020187000766A patent/KR20180035787A/ko not_active Withdrawn
- 2016-06-09 MX MX2017015879A patent/MX2017015879A/es unknown
- 2016-06-09 EA EA201792487A patent/EA033892B1/ru not_active IP Right Cessation
- 2016-06-09 US US15/178,153 patent/US20160361345A1/en not_active Abandoned
- 2016-06-09 WO PCT/US2016/036753 patent/WO2016201137A1/en not_active Ceased
- 2016-06-09 JP JP2017564547A patent/JP2018517046A/ja not_active Withdrawn
- 2016-06-09 HK HK18107537.5A patent/HK1247856A1/zh unknown
- 2016-06-09 CN CN201680041193.2A patent/CN107847517A/zh active Pending
- 2016-06-09 EP EP16808313.7A patent/EP3307278A4/en not_active Withdrawn
- 2016-06-09 BR BR112017026287A patent/BR112017026287A2/pt not_active Application Discontinuation
- 2016-06-09 CA CA2988529A patent/CA2988529A1/en not_active Abandoned
- 2016-06-13 TW TW105118518A patent/TW201716070A/zh unknown
- 2016-10-07 US US15/288,876 patent/US9675634B2/en active Active
-
2017
- 2017-04-27 US US15/499,831 patent/US10258641B2/en active Active
- 2017-11-29 IL IL255991A patent/IL255991A/en unknown
- 2017-12-07 CL CL2017003152A patent/CL2017003152A1/es unknown
- 2017-12-12 ZA ZA201708414A patent/ZA201708414B/en unknown
-
2018
- 2018-09-18 US US16/134,028 patent/US10300086B2/en active Active
-
2019
- 2019-04-02 US US16/372,899 patent/US10709730B2/en active Active
- 2019-06-04 US US16/430,664 patent/US10933083B2/en active Active
-
2020
- 2020-09-29 US US17/036,148 patent/US11406657B2/en active Active
-
2022
- 2022-05-16 US US17/745,497 patent/US11590160B2/en active Active
- 2022-05-16 US US17/745,505 patent/US11529366B2/en active Active
- 2022-05-16 US US17/745,491 patent/US11534456B2/en active Active
- 2022-05-16 US US17/745,481 patent/US11541074B2/en active Active
- 2022-05-16 US US17/745,470 patent/US11510940B2/en active Active
- 2022-05-16 US US17/745,464 patent/US11590159B2/en active Active
- 2022-05-16 US US17/745,487 patent/US11534455B2/en active Active
- 2022-05-16 US US17/745,516 patent/US11517585B2/en active Active
- 2022-09-16 US US17/946,670 patent/US11633423B2/en active Active
- 2022-10-20 US US17/970,080 patent/US11938144B2/en active Active
- 2022-11-30 US US18/072,260 patent/US11744848B2/en active Active
-
2023
- 2023-03-01 US US18/115,901 patent/US11744850B2/en active Active
- 2023-03-01 US US18/115,898 patent/US11865136B2/en active Active
- 2023-03-01 US US18/115,897 patent/US11744849B2/en active Active
- 2023-04-03 US US18/130,132 patent/US11826318B2/en active Active
- 2023-05-01 US US18/141,832 patent/US11918601B2/en active Active
- 2023-12-08 US US18/533,373 patent/US12611421B2/en active Active
-
2025
- 2025-01-17 US US19/028,631 patent/US12414964B2/en active Active
- 2025-02-24 US US19/061,509 patent/US12397015B2/en active Active
- 2025-02-24 US US19/061,577 patent/US12343358B2/en active Active
- 2025-04-10 US US19/175,757 patent/US12453741B2/en active Active
- 2025-05-27 US US19/219,596 patent/US12478635B2/en active Active
- 2025-07-17 US US19/272,439 patent/US20250352571A1/en active Pending
- 2025-07-23 US US19/278,380 patent/US12642813B2/en active Active
- 2025-07-23 US US19/278,356 patent/US12636306B2/en active Active
- 2025-07-23 US US19/278,422 patent/US12648960B2/en active Active
- 2025-08-28 US US19/312,906 patent/US12667587B2/en active Active
- 2025-10-06 US US19/350,933 patent/US12667588B2/en active Active
- 2025-10-06 US US19/350,939 patent/US12661371B2/en active Active
- 2025-10-06 US US19/350,944 patent/US12611422B2/en active Active
- 2025-10-28 US US19/371,542 patent/US12691137B2/en active Active
- 2025-10-28 US US19/371,517 patent/US12667589B2/en active Active
- 2025-10-28 US US19/371,529 patent/US12702678B2/en active Active
- 2025-10-28 US US19/371,584 patent/US12702679B2/en active Active
- 2025-12-02 US US19/406,162 patent/US12691138B2/en active Active
- 2025-12-02 US US19/406,305 patent/US20260097067A1/en active Pending
- 2025-12-02 US US19/406,290 patent/US20260097066A1/en active Pending
- 2025-12-02 US US19/406,370 patent/US20260097068A1/en active Pending
- 2025-12-02 US US19/406,190 patent/US12702680B2/en active Active
- 2025-12-02 US US19/406,402 patent/US20260097069A1/en active Pending
-
2026
- 2026-04-06 US US19/639,700 patent/US20260232719A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024013963A (es) | Un antagonista de il-4r util para el tratamiento o la prevencion del asma | |
| CL2023002252A1 (es) | Un complejo novedoso que comprende un péptido penetrante de células, una carga y un agonista | |
| SV2017005461A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| ECSP18017254A (es) | Composiciones con potenciadores de permeación para suministro de fármacos | |
| CO2017006580A2 (es) | Anticuerpos humanos para hemaglutinina de influenza | |
| BR112018003985A2 (pt) | macrociclos peptidomiméticos e usos dos mesmos | |
| CO2020009670A2 (es) | Composiciones que comprenden microbiota coseleccionada y métodos para su uso | |
| PE20180260A1 (es) | Metodos y kits para tratar la depresion | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| CL2017003436A1 (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso | |
| CO2017001994A2 (es) | Compuestos activos hacia bromodominios | |
| MX2021008113A (es) | Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma. | |
| MX387720B (es) | Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de conductancia de transmembrana de fibrosis quística. | |
| EA201790787A1 (ru) | Снижение вязкости фармацевтических составов | |
| BR112014021498A2 (pt) | composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado | |
| GT200900201A (es) | Formulaciones para el tratamiento del cáncer. | |
| CR20170259A (es) | Terapias de envenenamiento y composiciones farmacéuticas, sistemas y equipos relacionados | |
| BR112017026287A2 (pt) | composições de hidroxipropil beta-ciclodextrina e métodos | |
| BR112017003346A2 (en) | pyrazolopyridine derivatives, their uses, and pharmaceutical composition | |
| CO2017002472A2 (es) | Formulación de acetato de abiraterona | |
| UY37800A (es) | AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO | |
| DOP2018000034A (es) | Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas | |
| CL2020001062A1 (es) | Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos. | |
| MX2022013283A (es) | Composiciones para limpieza de colon y tratamiento de trastornos gastrointestinales. | |
| BR112017023425A2 (pt) | combinações terapêuticas de terapias antivirais e anti-inflamatórias |